Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
By Annika Kim Constantino
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
By Annika Kim Constantino
Full Coverage of this storyPfizer bid to expand Talzenna label in prostate cancer rejected by FDA
By Dulan Lokuwithana
FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC
FDA Advisors Reject Pfizer’s Bid to Broaden Talzenna Use as AI Explored for Clinical Trial Diversity
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
FDA Approves Label Update But Not Expansion for Talazoparib/Enzalutamide in mCRPC
By Jordyn Sava
Full Coverage of this storyFDA asks mRNA vaccine makers to widen age range for rare heart risk warning
By Elizabeth Cooney
PFE Stock Analysis: What is the price target for PFE in 2025?
By Frances Kai-Hwa Wang
NATO for medicines? Pfizer CEO calls for higher drug spending outside US amid Trump's MFN pricing push
By Angus Liu
Drug pricing reform talks with US government lack clarity, industry executives say
By Christy Santhosh & Bhanvi Satija
Medicaid Is Not a Test Lab for Foreign Price Controls – Commentary
Opinion
By Sally Pipes
Most Favored Nation Has No Place in U.S. Healthcare
Satya Marar: Trump doing the right thing in the wrong way (Opinion)
Opinion
By Satya Marar
Full Coverage of this storyWas Jim Cramer Right About Pfizer Inc. (PFE)?
By Dionysis Partsinevelos
Exclusive | New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel
By Annie Linskey & Josh Dawsey
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (June 2025)
By Joel South
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare (NYSE:PFE)
By Daniel Schonberger
Should You Buy Pfizer Stock Right Now?
By Selena Maranjian
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
By Kinjel Shah
Full Coverage of this storyPfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707
Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity
By Amanda Lanier
Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud
By Angus Liu
Pfizer CEO talks Chinese due diligence, ADC synergies to justify $6B bet on 'fabulous' bispecific
By Paul Taylor
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
Full Coverage of this storyNovavax says its COVID vaccine produces fewer, milder reactions than Pfizer version
By Mary Van Beusekom
Pfizer leans on cost cuts to offset falling revenue
By Michael Erman & Bhanvi Satija
Pfizer stops commercialization of hemophilia gene therapy Beqvez
By Christy Santhosh
Jim Cramer’s Lightning Round: 8 Stocks in Focus
By Syeda Seirut Javed
UnitedHealth, CVS stocks drop as Pfizer cites Trump comments
By Dulan Lokuwithana
Pfizer to pay $59.7 million over kickbacks for migraine drug
By Jonathan Stempel
Jim Cramer Warns on Pfizer (PFE): “That 7.7% Yield Is Not a Sign of Strength – It's a Sign of Weakness”
By Syeda Seirut Javed
Obama's inversion curbs kill Pfizer's $160 bln Allergan deal
By Caroline Humer & Ransdell Pierson
Starboard-Pfizer battle strains Guggenheim's relationship with drugmaker
By Maria Heeter, Oliver Barnes & James Fontanella-Khan
GSK resolves patent lawsuit against Pfizer over RSV vaccines
By Blake Brittain
How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs
By Ben Hargreaves
What Investors Are Missing about Pfizer and Merck
By Jeffrey Sonnenfeld
Pfizer Inc. (PFE): “Dead Money… Close the Casket,” Says Jim Cramer
By Syeda Seirut Javed